Pay to Marwadi

Company Profile

AUROBINDO PHARMA LTD.

NSE : AUROPHARMABSE : 524804ISIN CODE : INE406A01037Industry : Pharmaceuticals & DrugsHouse : Aurobindo
BSE1089.4519.45 (+1.82 % )
PREV CLOSE (Rs.) 1070.00
OPEN PRICE (Rs.) 1071.60
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 131296
TODAY'S LOW / HIGH (Rs.)1064.75 1095.00
52 WK LOW / HIGH (Rs.)504.9 1177
NSE1088.75 18.4 (+1.72 % )
PREV CLOSE(Rs.) 1070.35
OPEN PRICE (Rs.) 1070.35
BID PRICE (QTY) 1088.75 (1104 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 2060466
TODAY'S LOW / HIGH(Rs.) 1064.05 1099.25
52 WK LOW / HIGH (Rs.)504.65 1177.1

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.28
TTM EPS (Rs.) 33.56
P/E Ratio 32.47
Book Value (Rs.) 329.19
Face Value (Rs.) 1
MCap (Rs. in Mn) 638350.82
Price/Earning (TTM) 28.11
Price/Sales (TTM) 5.72
Price/Book (MRQ) 3.31
PAT Margin (%) 9.55
ROCE (%) 8.44
Incorporation Year : 1986

Management Info :

K Ragunathan - Chairman K Nithyananda Reddy - Managing Director

Registered Office :

Address : Plot No. 2,Maitrivihar ,Ameerpet,
Hyderabad,
Telangana-500038

Phone : 040-23736370 / 23747340

Website : www.aurobindo.com

Registrar's Details : K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
20Mar03-20-2024$Aurobindo Pharma gets final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray Aurobindo Pharma gets final

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25.

The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 507 ANDA approvals (488 Final approvals and 19 tentative approvals) from USFDA.

Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and paediatric patients 2 years of age and older.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma has received final approval from the US Food &..
20Mar03-20-2024$Aurobindo Pharma rises on getting final nod to manufacture, market Mometasone Furoate Monohydrate Nasal Spray Aurobindo Pharma rises on ge

Aurobindo Pharma is currently trading at Rs. 1004.05, up by 14.65 points or 1.48% from its previous closing of Rs. 989.40 on the BSE.

The scrip opened at Rs. 1006.45 and has touched a high and low of Rs. 1013.90 and Rs. 996.00 respectively. So far 8516 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 466.00 on 21-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1022.35 and Rs. 985.05 respectively. The current market cap of the company is Rs. 57972.77 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.32% and 6.85% respectively.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nasonex Nasal Spray, 50 mcg/spray of Organon LLC. The product will be launched in Q1FY25.

The approved product has an estimated market size of $44.5 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 507 ANDA approvals (488 Final approvals and 19 tentative approvals) from USFDA.

Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray, is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and paediatric patients 2 years of age and older.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma is currently trading at Rs. 1004.05, up by 14...
13Mar03-13-2024$Aurobindo Pharma’s arm restarts distribution of aseptic products manufactured at Unit III Aurobindo Pharma’s arm res

Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Specialities has started distribution of aseptic products manufactured at Unit III, that was temporarily stopped. The company also expects to start commercial production from the aseptic lines of the said facility in a phased manner beginning next week and to re-start all the lines by April 15, 2024.

Earlier, Eugia Pharma Specialities had restarted production in its terminally sterilized product lines at its Unit-III. The production was temporarily stopped to address some of the observations of United States Food and Drug Administration (USFDA) in their recent inspection concluded on February 2, 2024. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Spe..
06Mar03-06-2024$Aurobindo Pharma informs about media meet Aurobindo Pharma informs abo

Aurobindo Pharma has informed that the officials of the Company will be participating in the Media group meeting arranged by Ad factors on March 13, 202 at 4 03:45 am to 04:45 pm (IST) in Hyderabad. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.

The above information is a part of company’s filings submitted to BSE.

Aurobindo Pharma has informed that the officials of the Company..
04Mar03-04-2024$Aurobindo Pharma rises on getting final nod to manufacture, market Fingolimod Capsules, 0.5 mg Aurobindo Pharma rises on ge

Aurobindo Pharma is currently trading at Rs. 1097.35, up by 21.25 points or 1.97% from its previous closing of Rs. 1076.10 on the BSE.

The scrip opened at Rs. 1077.50 and has touched a high and low of Rs. 1097.35 and Rs. 1072.00 respectively. So far 3359 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1177.00 on 30-Jan-2024 and a 52 week low of Rs. 443.15 on 14-Mar-2023.

Last one week high and low of the scrip stood at Rs. 1097.35 and Rs. 1012.00 respectively. The current market cap of the company is Rs. 63052.85 crore.

The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 41.32% and 6.85% respectively.

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fingolimod Capsules, 0.5 mg, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation. The product will be launched in March 2024.

The approved product has an estimated market size of $447.3 million for the twelve months ending January 2024, according to IQVIA. Aurobindo now has a total of 505 ANDA approvals (486 Final approvals and 19 tentative approvals) from USFDA.

Fingolimod Capsules, 0.5 mg, is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma is currently trading at Rs. 1097.35, up by 21...
Financials More
Rs. in Millions
QTR Dec 23 ANNUAL 23
Net Profit6237.812304.1
Gross Profit 6872.2 16143.5
Operating Profit 8128.221646.8
Net Sales 26920.3127922.8
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 26946.00 (0.74%)
M.Cap ( in Cr)
57258.37
Sanofi India (BSE)
 8118.25 (2.06%)
M.Cap ( in Cr)
18696.83
Dr. Reddy's Lab (BSE)
 6155.15 (1.78%)
M.Cap ( in Cr)
102679.14
Divi's Lab (BSE)
 3436.75 (2.14%)
M.Cap ( in Cr)
91234.91
Glaxosmithkline Phar (BSE)
 1943.10 (3.26%)
M.Cap ( in Cr)
32917.29
Shareholding Pattern More
NON-INSTITUTION 6.85 %
PROMOTERS 51.83 %
FI/BANKS/INSURANCE 5.53 %
MUTUAL FUNDS/UTI 14.7 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes